5.23
5.23 (0%)
As of Feb 14, 2025
Cytek Biosciences, Inc. [CTKB]
Source:
Company Overview
Cytek Biosciences, Inc is a leading cell analysis solutions company advancing the next generation of research and clinical tools with our novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells (“Full Spectrum Profiling” or “FSP” technology). O
| Country | United States |
| Headquarters | fremont, california |
| Phone Number | (877) 922-9835 |
| Industry | manufacturing |
| CEO | Wenbin Jiang, Ph.D. |
| Website | www.cytekbio.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $200.5 |
| Operating Profit | $-20.5 |
| Net Income | $-6 |
| Net Cash | $-68.9 |
Profit Ratios
| Gross Margin | $111.1 |
| Operating Margin | -10.2 |
| Profit as % of Revenues | -1,845.6% |
| Profit as % of Assets | -1.2% |
| Profit as % of Stockholder Equity | -1.5% |
Management Effectiveness
| Return on Equity | -1.5% |
| Return on Assets | -1.2% |
| Turnover Ratio | 40.3% |
| EBITA | $-20.5 |
Balance Sheet and Cash Flow Measures
| Total Assets | $499.5 |
| Total Liabilities | $103.8 |
| Operating Cash Flow | $25.4 |
| Investing Cash Flow | $-83 |
| Financing Cash Flow | $-15.8 |
